HELIXMITH CO., LTD
14Patents
13Active
14Granted
47Portfolio score
Filing activity: Oct 22, 2014 → Nov 13, 2019
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10927177B2 | Methods of treatment using anti-c-met antibodies | Chemistry; Metallurgy | 1 | Active |
| US11554179B2 | Lyophilized pharmaceutical compositions for naked DNA gene therapy | Chemistry; Metallurgy | 0 | Active |
| US11464875B2 | Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms | General | 0 | Revoked |
| US11559555B2 | Crude drug composition for preventing or treating respiratory diseases | Human Necessities | 0 | Active |
| US11510999B2 | Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms | Emerging Cross-Sectional Technologies | 0 | Active |
| US11634728B2 | Adeno-associated virus (AAV) vector having hybrid HGF gene introduced thereto | Chemistry; Metallurgy | 0 | Active |
| US10759841B2 | Gene therapy for diabetic neuropathy using an HGF isoform | Human Necessities | 0 | Active |
| US12180287B2 | Anti-c-Met antibody showing enhanced stability or antigen-binding fragments thereof | Chemistry; Metallurgy | 0 | Active |
| USRE48404E1 | Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor | General | 0 | Active |
| US11975039B2 | Herbal composition for treatment of attention deficit hyperactivity disorder | Human Necessities | 0 | Active |
| US11541097B2 | Crude drug composition for preventing or treating respiratory diseases | Human Necessities | 0 | Active |
| US11279769B2 | Anti-Sialyl Tn chimeric antigen receptors | Chemistry; Metallurgy | 0 | Active |
| US10639351B2 | Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor | Chemistry; Metallurgy | 0 | Active |
| US11219667B2 | Method for treating peripheral vascular disease using hepatocyte growth factor and stromal cell derived factor 1A | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.